Course Overview

CMHC’s Foundations of Cardiometabolic Health Certificate Course will provide an introductory review of the core curriculum in cardiometabolic health.

This course is designed for any healthcare professional seeking to learn the fundamentals of the intersections of cardiometabolic risk factors, and the core principles in the management of obesity, type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, chronic kidney disease, care delivery implementation, and cardiometabolic considerations in racial & ethnic minorities. The course will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in their respective practices, in addition to preparing clinicians for the inevitable future of cardiometabolic-specific clinics.

The Foundations of Cardiometabolic Health Certificate Course is appropriate for clinicians from a full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists, Diabetologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into cardiometabolic health.

Course Status:  ALL MODULES of the Foundations of Cardiometabolic Health Certificate Course are live! 

Course Objectives

After completing this activity, the participant should be better able to:

  • Review the impact of diet and diet quality on cardiometabolic health.
  • Describe common elements of healthful eating patterns to promote cardiometabolic health according to evidence-based recommendations and guidelines.
  • Discuss physical activity guidelines for patients with chronic health conditions or with cardiometabolic risk factors.
  • Discuss the connections between sleep disorders or poor sleep and cardiometabolic health
  • Review the clinical presentation of various sleep disorders and their associated treatment options.
  • Develop individualized and comprehensive lifestyle approaches to reduce cardiometabolic risk, including incorporating healthful eating patterns, physical activity, smoking cessation advice, and assessment and adequate referral for sleep disorders.

After completing this activity, the participant should be better able to:

  • Define obesity as a treatable disease and incorporate practical approaches for its screening and diagnosis.
  • Summarize the efficacy and safety of lifestyle interventions and weight loss pharmacotherapy in the treatment of patients with obesity.
  • Discuss the efficacy and safety of metabolic surgery in the treatment of obesity, as well as improving cardiometabolic outcomes.
  • Review the burden, pathophysiology and impacts of NAFLD and NASH.
  • List current and emerging strategies for the screening, diagnosis, and treatment of NAFLD and NASH.
  • Develop comprehensive individualized treatment options for patients with obesity that promote and sustain weight loss.

After completing this activity, the participant should be better able to:

  • Identify risk factors, as well as screening and diagnostic criteria in order to identify patients with type 2 diabetes or prediabetes in a timely manner.
  • Discuss efficacy and safety of medication classes for type 2 diabetes.
  • Review current guidelines and evidence-base for the individualization of T2DM therapy.
  • List the efficacy and safety of approaches for intensive glycemic management in patients with type 2 diabetes, including continuous glucose monitoring, insulins, and insulin delivery systems.
  • Select evidence-based therapy for patients with type 2 diabetes and comorbidities such as ASCVD, HF, or CKD.

After completing this activity, the participant should be better able to:

  • Outline strategies for the timely screening and diagnosis of hypertension.
  • Review the efficacy and safety of out-of-office vs. in-office blood pressure measurements.
  • Explain evidence-based approaches for screening and diagnosing resistant hypertension.
  • Summarize the efficacy and safety of pharmacological and non-pharmacological approaches for the treatment of hypertension.
  • Develop individualized treatment options for patients with hypertension based on current evidence-base and guideline recommendations.

After completing this activity, the participant should be better able to:

  • List current and emerging treatment options for lipid lowering, including for hypercholesterolemia, hypertriglyceridemia, and elevated lipoprotein a.
  • Recognize the burden of other lipid players beyond LDL-C in the development of atherosclerosis and residual ASCVD risk.
  • Develop individualized treatment options for patients with dyslipidemia based on current treatment options and guideline recommendations.

After completing this activity, the participant should be better able to:

  • Summarize the burden, risk factors, and screening criteria for CAD or PAD.
  • Review current guidelines for antithrombotic therapy in patients with CAD or PAD.
  • Discuss risk factors, symptom presentation, stages and classification of heart failure.
  • Review recent advances in HF therapies and clinical guidelines.
  • List screening criteria and technological advances for the identification of common arrhythmias.
  • Explain current treatment options and guidelines for the prevention and treatment of common arrhythmias, including stroke prevention in patients with arrhythmias.
  • Summarize current evidence and guidelines about antithrombotic therapy in patients with a recent ACS event.
  • Recognize the significant burden of CVD in women, as well as specific differences in risk factors and symptoms presentation.

After completing this activity, the participant should be better able to:

  • Review the pathophysiology, disease burden, and risk factors for CKD.
  • Identify patients at risk for CKD based on recommended screening and diagnostic practices.
  • Summarize available treatment options for CKD that preserve kidney function and slow CKD progression.

After completing this activity, the participant should be better able to:

  • Recognize the need for improved care coordination in the treatment of cardiometabolic patients.
  • Outline practical steps and strategies to enhance team-based care, multidisciplinary collaboration, and patient education to improve outcomes for cardiometabolic patients across the care continuum.

After completing this activity, the participant should be better able to:

  • Discuss the disproportionate burden of cardiometabolic disease and cardiometabolic risk in racial and ethnic minorities.
  • Identify and address clinical, behavioral, and cultural factors that contribute to the increased cardiometabolic burden in racial and ethnic minorities.
  • Summarize individualized risk assessment approaches and tailored therapy for treatment of cardiometabolic risk or diseases, including type 2 diabetes, hypertension, dyslipidemia, obesity, and cardiovascular disease, in patients from racial and ethnic minorities.


Discuss the interrelationships between cardiometabolic risk factors and their impact on the development of cardiometabolic diseases, including obesity, diabetes, ASCVD, heart failure, type 2 diabetes, and chronic kidney disease.


Summarize the evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease.


Discuss key clinical trials and recent therapeutic updates across the interconnected domains of cardiometabolic medicine, including lifestyle, obesity, type 2 diabetes, hypertension, cardiovascular disease, and chronic kidney disease.


Outline strategies aimed at timely screening and prevention of cardiometabolic disease, including the importance of lifestyle modifications and evidence-based screening and diagnostic modalities.


Describe treatment approaches for cardiometabolic conditions in specific populations based on gender, ethnicity, and cultural considerations.


Develop individualized treatment regimens for patients with cardiometabolic disease according to evidence-based comprehensive treatment approaches, as well as patient comorbidities and preferences in order to optimize outcomes.

Course Chair

Robert H. Eckel, MD
  • Professor of Medicine, Emeritus
  • Division of Endocrinology, Metabolism & Diabetes
  • Division of Cardiology
  • S/P Professor of Physiology & Biophysics
  • S/P Charles A. Boettcher II Chair in Atherosclerosis
  • University of Colorado Anschutz Medical Campus
  • Aurora, Colorado

Certificate Course Overview

The course will be organized by 9 focus areas, each of which will host their own testing and evaluation methods in order for learners to self-direct their learning and complete the course at their own pace. A certificate of completion and/or CME/CE credit(s) will be provided after a learner completes each focus area.

Upon completion of all focus areas, learners will receive a certificate acknowledging their successful completion of the Foundations of Cardiometabolic Health Certificate Course.

Learners will have 1 year after starting the Foundations of Cardiometabolic Health Certificate Course to complete all focus areas and complete the course curriculum.

Course Focus Areas

50+ Hours (Online)

Alice H. Lichtenstein, D.Sc; Linda Shiue, MD
  • Introduction to Nutrition & Cardiometabolic Health
  • The Role of Nutrition in Cardiometabolic Health
  • Assessment of nutritional status
  • Nutritional therapy and components
  • Guideline recommendations
  • Culinary medicine & Practical Nutritional Approaches

Physical Activity
John M. Jakicic, PhD
  • Introduction to Physical Activity & Cardiometabolic Health
  • The Role of Physical Activity in Cardiometabolic Health
  • Physical Activity Recommendations
  • Types of physical activity and evidence for cardiometabolic health
  • What type of PA is most beneficial based on underlying comorbidity (or comorbidities)

Smoking Cessation
Hilary A. Tindle, MD
  • Introduction/overview–role of smoking in increasing cardiometabolic risk
  • Assessment and screening of smoking status
  • Behavioral interviewing
  • Evidence-based strategies for smoking cessation (smoking cessation pharmacology, alternative tobacco products & more)

Sleep Medicine
Lee A. Surkin, MD; Christopher J. Lettieri, MD
  • Introduction/overview: The impact of sleep disorders on cardiometabolic risk/disease
  • Classification of sleep disorders
  • Assessment, diagnosis, clinical manifestations and management of sleep disorders

Obesity as a Disease/Overview
Karli Burridge, PA-C, MMS, FOMA

  • Introduction to Obesity: Epidemiology, Burden, Impact on Cardiometabolic Health
  • Screening and Diagnosing Obesity
  • How to Initiate Discussion with Patients & Communication Strategies
  • Behavioral/motivational interviewing


Medical Management of Obesity
Donna H. Ryan, MD

  • Treating Obesity to the Standard of Care: Rationales, Principles, Comprehensive Considerations
  • Medicating the Patient with Obesity: Current and New Approaches to Help with Weight Loss and Weight Loss Maintenance


Metabolic Surgery
Christopher D. Still, DO 

  • Efficacy and Safety
  • Mechanisms of Action
  • Role in Reducing Cardiometabolic Risk Beyond Obesity (Diabetes & CVD risk)
  • Indications/Guidelines


Kenneth Cusi, MD; Christos S. Mantzoros, MD

  • Epidemiology, Pathophysiology, Mechanisms
  • Risk factors and Screening
  • Diagnosis (from non-invasive to invasive)
  • Therapeutic lifestyle management
  • Current Pharmacologic management
  • Emerging Pharmacotherapies & treatment targets

Diabetes Screening/Diagnosis
Kathleen Dungan, MD, MPH

  • Prevention & Delay of T2D/prediabetes
  • Classification
  • Diagnostic tests
  • Prediabetes
  • Comprehensive evaluation & assessment of comorbidities

Pharmacologic Approaches
Lauren C. Vincent, MD;
Athena Philis-Tsimikas, MD

  • Goals of therapy/glycemic targets
  • Overview of efficacy and safety of different classes
  • Overview of guidelines
  • Stepwise approach to therapy
  • Therapy according to comorbidities/ risk factors (HF, ASCVD, CKD)

Intensive/Advanced Glycemic Management
Irl B. Hirsch, MD; Anne L. Peters, MD

  • Continuous Glucose Monitoring (CGM): Rationale & Overview
  • Pumps, Insulin Delivery Systems, and Connected Insulin Pens
  • Injectable Therapies for Diabetes (Insulin and Non-Insulin Injectables)
Hypertension Definition/Screening/Diagnosis
Luke J. Laffin, MD
  • Overview/Epidemiology/Burden
  • Pathophysiology
  • Definition, measurements & diagnosis (including out-of-office BP measurements)
  • Risk factors and inducers of hypertension
Pharmacologic treatments
George L. Bakris, MD
  • Lifestyle modification
  • Pharmacological treatment & guidelines
  • Adherence to antihypertensive treatment
Resistant Hypertension
George L. Bakris, MD
  • Detection
  • Evaluation
  • Management
Introduction/Overview Alan Chait, MD
  • Pathophysiology & Vascular Biology
  • Classification, Measurement and Metabolism of Lipids and Lipoproteins
  • Cholesterol, lipoproteins, and ASCVD risk

Screening and Treatment of Hypercholesterolemia Christie M. Ballantyne, MD; Maya Vadiveloo, PhD, RD; Pam R. Taub, MD
  • ASCVD risk factors & risk enhancers
  • Identification, testing and ASCVD risk assessment
  • Lifestyle modifications for lipid lowering
  • Pharmacologic treatment (current guidelines, efficacy and safety of statin and non-statin therapies)

Residual ASCVD Risk & Other Players in Dyslipidemia Robert H. Eckel, MD; Sotirios Tsimikas, MD
  • Hypertriglyceridemia: Association or causative for ASCVD management
  • HTG targets
  • Review of HTG management strategies, from moderate to severe HTG
  • HDL and HDL science/management
  • Lipoprotein (a) science/evidence/management, emerging therapies

Advanced Non-Invasive Cardiac Imaging
Michael J. Blaha, MD; Kunal Jha, MD

  • Risk Assessment of the Asymptomatic Patient – Primary Prevention
  • Non-Invasive Imaging Evaluation of the Symptomatic Patient
  • Non-Invasive Imaging Discussion Cases: Risk Assessment, Anatomic vs. Functional Approach


Vascular Medicine and Thrombosis
Deepak L. Bhatt, MD; Marc P. Bonaca, MD

  • PAD, CAD
  • Epidemiology, burden
  • Screening, risk factors, diagnosis
  • Guidelines & management


Acute Coronary Syndromes

  • Definitions, Pathophysiology, and Epidemiology of ACS
  • Diagnosis, Risk Stratification, and Revascularization
  • Medical Therapy


William H. Sauer, MD; Usha B. Tedrow, MD; Sunil Kapur, MD

  • Overview of Cardiac Arrhythmias and Treatment Options
  • Atrial Fibrillation: Epidemiology, Modifiable Risk Factors, and Concept of Atrial Fibrillation as a Systemic Illness
  • Strategies for Prevention of Stroke Associated with Atrial Fibrillation


Heart Failure
Alanna A. Morris, MD ; Ileana L. Piña, MD

  • Overview, epidemiology, pathophysiology, burden
  • Heart failure & cardiometabolic risk connections
  • Screening and diagnostic approaches
  • Management of Heart Failure (guidelines, spectrum of therapies/treatment table/efficacy and safety, newer therapies)


CVD Considerations in Women
Pam R. Taub, MD

  • Overview of Cardiometabolic Disease and Cardiometabolic Risk Across the Lifespan of Women
  • Unique Aspects of Coronary Artery Disease, Heart Failure, and Valvular Heart Disease in Women
  • Women-specific CVD Risk Factors Across the Lifespan

CKD Spectrum
George L. Bakris, MD; Kim Zuber, PAC

  • Pathophysiology and Epidemiology of Chronic Kidney Disease
  • Stages of CKD and Associated Risks
  • Screening, Diagnosis, and Prediction of CKD Progression
  • Treatment of CKD, Stages 1-4

Care Delivery Implementation
Mikhail N. Kosiborod, MD; Michael J. Blaha, MD;
Melissa Magwire, RN, MSN, CDE

  • Rationale/reason for multidisciplinary care
  • Perspectives on team-based care, care coordination, practical tips, patient/staff education

Cardiometabolic Considerations in Racial and Ethnic Minorities

Keith C. Ferdinand, MD

  • Overview: Cardiometabolic Disparities & Inequities
  • Hypertension in Racial/Ethnic Populations
  • Heart Failure and Sudden Death
  • Diabetes and Heart Failure
  • Heart Failure with Preserved Ejection Fraction (HFpEF)
  • Lipids in Racial/Ethnic Populations
  • Eliminating Disparities: Perspectives & Strategies

Foundations Learner Access Site

By registering for the Foundations of Cardiometabolic Health Certificate Course, learners also gain access to an exclusive gated site containing news, course updates, faculty insights, and more resources directly related to all of the course module topics.

Registered learners will receive access information by email. If you have enrolled in the course but have not received your access credentials, please email [email protected].

Certificate Course Cost

Single License
Student/Fellow License (Must Provide Proof)
Bulk Pricing: Up to 5 Licenses
Bulk Pricing: Up to 10 Licenses
Bulk Pricing: Up to 25 Licenses
Bulk Pricing: Up to 50 Licenses
Bulk Pricing: Up to 75 Licenses
Bulk Pricing: 75+ Licenses
Contact for Pricing
Slide table to see all pricing options
*Discounts provided for bulk license purchases – inquire for more information.




In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners for Advancing Clinical Education designates this enduring material for a maximum of 50.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 50.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Partners for Advancing Clinical Education designates this continuing education activity for 50.75 contact hour(s) (5.075 CEUs) of the Accreditation Council for Pharmacy Education.

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 50.75 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 50.75 MOC points in the American Board of Internal Medicine’s (ABIM) maintenance of certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


A computer with an internet connection.

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.


Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.